Market research
LX31.F Lexicon Pharmaceuticals, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 420M
- P/E ratio
- 11.62
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.46
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 420M
- P/E ratio
- 11.62
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.46
About
About Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LX31.F discussion.
5 years, 5 months ago
Lexicon Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 11.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.4.
Lexicon Pharmaceuticals, Inc's total revenue sank by 97.7% to $199K since the same quarter in the previous year.
Its net income has increased by 89.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.7% to $-34M since the same quarter in the previous year.
Based on the above factors, Lexicon Pharmaceuticals, Inc gets an overall score of 2/5.